Results 131 to 140 of about 4,520 (170)
Some of the next articles are maybe not open access.
A tale of two drugs: Molnupiravir and Paxlovid
Mutation Research - Reviews in Mutation ResearchThe orally administered antiviral drug Lagevrio or molnupiravir (MOV) and the combination antiviral drug nirmatrelvir/ritonavir or Paxlovid (PAX) have been shown to reduce the likelihood of hospitalization and death for high-risk patients with COVID-19.
Michael D. Waters, Stafford G. Warren
openaire +2 more sources
Epidemiological Study of the Effectiveness of Paxlovid
Clinical Infectious Diseases, 2022Hui-Yuan Chen +2 more
openaire +2 more sources
Nirmatrelvir-Ritonavir (Paxlovid)
Canadian Journal of Health TechnologiesCADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +1 more source
A Television Interview with Paxlovid
Daxue Huaxue, 2022Minghong Yang +3 more
openaire +1 more source
Safety Profile of Paxlovid in the Treatment of COVID-19
Current Pharmaceutical DesignBackground: With the urgent and widespread application of Paxlovid, a novel antiviral drug for Coronavirus Disease 2019 (COVID-19) in clinical practice, concerns regarding its actual efficacy and safety have emerged. In order to provide more evidence to support its clinical application, we sought to perform a descriptive analysis of cases who ...
Bing Lv +4 more
openaire +2 more sources